[Neuroprotective therapy for amyotrophic lateral sclerosis (ALS)].
Amyotrophic lateral sclerosis (ALS) is a typical intractable disease affecting the primary and secondary motoneurones resulting in generalized muscular atrophy and weakness with or without spasticity. Dysphagia, dysarthria, and respiratory difficulty are symptoms which cause restriction of ADL and death. Recent achievement in understanding neuronal death in ALS has invited trials on various drugs aiming at neuroprotection and prolongation of the course of ALS. They include inhibition of excitotoxicity of amino acids, suppression of free radicals by lecithinized SOD and various neurotrophic factors. Significant prolongation of life span was obtained by riluzole in a US-Europe trial, but the effects were insignificant in the Japanese nation-wide trial.
Yanagisawa
N
N
Department of Medicine (Neurology), Shinshu University School of Medicine.
Shindo
M
M
D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy*; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D019782:Riluzole; D013844:Thiazoles / Q000627:therapeutic use
D018696:Neuroprotective Agents; D013844:Thiazoles; D019782:Riluzole